{"id":251484,"date":"2025-11-05T00:00:00","date_gmt":"2025-11-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidwh0004-biopharma-genitourinary-syndrome-of-menopause-epidemiology-2\/"},"modified":"2026-03-31T10:24:28","modified_gmt":"2026-03-31T10:24:28","slug":"epidwh0004-biopharma-genitourinary-syndrome-of-menopause-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidwh0004-biopharma-genitourinary-syndrome-of-menopause-epidemiology-mature-markets\/","title":{"rendered":"Genitourinary Syndrome of Menopause &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of <abbr data-abbreviation-entity=\"8520\" title=\"genitourinary syndrome of menopause\">GSM<\/abbr> comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of <abbr data-abbreviation-entity=\"8520\" title=\"genitourinary syndrome of menopause\">GSM<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>All patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr data-abbreviation-entity=\"8520\" title=\"genitourinary syndrome of menopause\">GSM<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"8520\" title=\"genitourinary syndrome of menopause\">GSM<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr data-abbreviation-entity=\"10739\" title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts seven <abbr data-abbreviation-entity=\"8520\" title=\"genitourinary syndrome of menopause\">GSM<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Total <abbr data-abbreviation-entity=\"8520\" title=\"genitourinary syndrome of menopause\">GSM<\/abbr> prevalent cases<\/li>\n<li>Total <abbr data-abbreviation-entity=\"8520\" title=\"genitourinary syndrome of menopause\">GSM<\/abbr> prevalent cases with stress urinary incontinence<\/li>\n<li>Total <abbr data-abbreviation-entity=\"8520\" title=\"genitourinary syndrome of menopause\">GSM<\/abbr> prevalent cases with dysuria<\/li>\n<li>Total <abbr data-abbreviation-entity=\"8520\" title=\"genitourinary syndrome of menopause\">GSM<\/abbr> prevalent cases with symptomatic pelvic organ prolapse<\/li>\n<li>Total <abbr data-abbreviation-entity=\"8520\" title=\"genitourinary syndrome of menopause\">GSM<\/abbr> prevalent cases with fecal incontinence<\/li>\n<li>Total <abbr data-abbreviation-entity=\"8520\" title=\"genitourinary syndrome of menopause\">GSM<\/abbr> prevalent cases with urinary frequency<\/li>\n<li>Total <abbr data-abbreviation-entity=\"8520\" title=\"genitourinary syndrome of menopause\">GSM<\/abbr> prevalent cases with urgency\u00a0urinary incontinence<\/li>\n<\/ul>\n<p>Note: coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251484","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-genitourinary","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251484\/revisions"}],"predecessor-version":[{"id":571926,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251484\/revisions\/571926"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}